Mather Group LLC. Increases Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Mather Group LLC. boosted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 38.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,592 shares of the company’s stock after purchasing an additional 1,546 shares during the period. Mather Group LLC.’s holdings in Novo Nordisk A/S were worth $798,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of NVO. GQG Partners LLC raised its stake in shares of Novo Nordisk A/S by 654.6% in the 1st quarter. GQG Partners LLC now owns 3,633,064 shares of the company’s stock valued at $466,485,000 after acquiring an additional 3,151,584 shares during the period. Capital International Investors raised its holdings in shares of Novo Nordisk A/S by 22.3% in the 4th quarter. Capital International Investors now owns 7,114,931 shares of the company’s stock valued at $736,121,000 after buying an additional 1,297,536 shares during the period. Acadian Asset Management LLC lifted its stake in Novo Nordisk A/S by 1,300.8% during the 1st quarter. Acadian Asset Management LLC now owns 1,244,128 shares of the company’s stock worth $159,703,000 after acquiring an additional 1,155,313 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Novo Nordisk A/S by 10.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 8,589,222 shares of the company’s stock valued at $1,102,857,000 after acquiring an additional 823,036 shares during the period. Finally, International Assets Investment Management LLC grew its position in Novo Nordisk A/S by 10,359.2% in the 4th quarter. International Assets Investment Management LLC now owns 819,688 shares of the company’s stock valued at $84,797,000 after acquiring an additional 811,851 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. BMO Capital Markets reiterated an “outperform” rating and set a $163.00 target price on shares of Novo Nordisk A/S in a report on Tuesday, June 25th. The Goldman Sachs Group initiated coverage on Novo Nordisk A/S in a research note on Thursday, May 30th. They issued a “buy” rating and a $156.00 price objective on the stock. Argus boosted their target price on Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, June 10th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Monday. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Moderate Buy” and a consensus price target of $145.67.

Novo Nordisk A/S Stock Down 8.0 %

Novo Nordisk A/S stock traded down $10.40 during midday trading on Wednesday, reaching $119.72. The company’s stock had a trading volume of 7,842,733 shares, compared to its average volume of 4,456,692. The company has a market cap of $537.25 billion, a P/E ratio of 42.03, a P/E/G ratio of 1.33 and a beta of 0.41. The company has a quick ratio of 0.50, a current ratio of 0.70 and a debt-to-equity ratio of 0.17. The business has a 50-day simple moving average of $137.93 and a 200-day simple moving average of $129.65. Novo Nordisk A/S has a fifty-two week low of $86.96 and a fifty-two week high of $148.15.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.